Trial Profile
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending, Single- and Multiple-Oral-Dose, Safety, Tolerability, and Pharmacokinetic Study of GDC-3280 in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Jan 2020
Price :
$35
*
At a glance
- Drugs AK 3280 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Genentech
- 08 Jan 2020 According to an Ark Biosciences media release, updates from this study will be presented at the JP Morgan Healthcare Conference on January 15th 2020.
- 16 Mar 2016 Status changed from recruiting to completed, according to ClinicalTrials.gov record.
- 25 Jun 2015 New trial record